5326602026-01-012026-03-315326602026-03-315326602025-03-315326602025-04-012026-03-315326602026-01-012026-03-31in-capmkt:OtherExpenses1Member5326602026-01-012026-03-31in-capmkt:OtherExpenses2Member5326602025-04-012026-03-31in-capmkt:OtherExpenses1Member5326602025-04-012026-03-31in-capmkt:OtherExpenses2Member5326602026-03-31OtherCurrentFinancialAssetsDomain15326602026-03-31OtherCurrentAssetsDomain15326602026-03-31OtherNoncurrentFinancialLiabilitiesDomain15326602026-03-31OtherNoncurrentLiabilitiesDomain15326602026-03-31OtherCurrentFinancialLiabilitiesDomain15326602026-03-31OtherCurrentLiabilitiesDomain15326602026-01-012026-03-31RelatedPartyTransactionDomain15326602025-12-31RelatedPartyTransactionDomain15326602026-03-31RelatedPartyTransactionDomain15326602026-01-012026-03-31AuditorDomain15326602026-01-012026-03-31in-capmkt:AuditedMember5326602026-03-31in-capmkt:AuditedMember5326602026-01-012026-03-31in-capmkt:AdjustedMember5326602026-03-31in-capmkt:AdjustedMember5326602026-01-012026-03-31AuditQualification15326602026-01-012026-03-31AuditQualification25326602026-01-012026-03-31AuditQualification35326602026-01-012026-03-31AuditQualification45326602026-01-012026-03-31AuditQualification55326602026-01-012026-03-31AuditQualification6iso4217:INRiso4217:INRxbrli:shares532660VIVIMEDLABNAINE526G01021VIVIMED LABS LIMITEDMain BoardEquity2025-04-012026-03-312026-07-172026-07-14INRMillionsQuarterlyFourth quarterSingle segmentPHARMA2026-07-1714:00:002026-07-1716:00:00trueCash Flow IndirectStatement on impact of audit qualificationtruetrueNANAfalsetrue2026-03-31www.vivimedlabs.comfalsetrue2026-01-012026-03-31AuditedStandalone754900004000075530000930500000365600000863800007910000430500008913100001487300000-14117700000-14117700000000-14117700000000-14117700000-141177000016583000010-17.14-16.6400-17.14-16.642025-04-012026-03-31AuditedStandalone557820000513000056295000032388000003837300002041300003857000018187000011376100002269790000-17068400000-17068400000000-17068400000000-17068400000-170684000016583000010380000000-20.59-19.9800-20.59-19.98Other Expenses900570000Items-9260000Other Expenses1146870000Items-9260000231418000017008000068700000481410000562730000000359710000010826000004336500006900000114000006057000050631000017879000063116000014245200005021620000165830000-1287770000-1121940000-11219400007135700001076290000178986000040320000903300004950000192546000031675000000516530000516530000114480000379851000022701000012540000180040000421810000061435600005021620000Other Finacial Assets60570000Other current assets631160000Other non-current financial liabilities1076290000Other non-current liabilities4950000Other current financial liabilities114480000Other current liabilities2270100000456730000243600000525610000004200000001549400000001818700000013480000017776000013356000000000385700000001748880000420400000-24300000004447000000000000-11300000000000000000000000000-11300000000000006970000003857000000-45540000-22000000-22000002890000690000000000VIVIMED LIMITED******Finoso Pharma Private Limited******SUBISIDARYAny other transactionSale and purchases-12570000NA-125700003217000019600000-12570000AuditedQualified opinionsvrl&cotrue2027-04-3056295000056295000022698000002873020000-1706850000-2310070000-20.59-27.865021620000502162000050216200005021620000-1121940000-1725160000As disclosed in Note 28 to the statement, the Company has not recognized an interest expense of approximately Rs.625.72 million on an accrual basis, as of March 31, 2026. A significant portion of this unrecorded interest, amounting to Rs.603.22 million, pertains to borrowings from State Bank of India that have been assigned to Rare Asset Reconstruction Company (ARC), as disclosed in Note 16(b)C to the statement. This is not in compliance with Indian accounting standards, which require accrual based accounting and recognition of borrowing costs when accrued. Consequently, the reported loss and liability is understated by the said amountQualified opinionRepetitiveThe Company’s borrowings from State Bank of India have been assigned to Rare Asset Reconstruction Company (ARC). Since the assignment, there has been no demand or communication from the ARC regarding interest liability. In the absence of any demand or confirmation of interest payable, the Company has not recognized interest expense as Interest without any contractual demand or confirmation would not reflect the substance of the transaction. The liability continues to be disclosed under borrowings, and the Company has made adequate disclosure in the Notes to Accounts regarding the assignment of debt to ARC.nanaNaWe are unable to obtain direct external confirmations in respect of the Company’s current and non current borrowings as referred in note 16a, 16b. Consequently, we are unable to comment on the completeness, accuracy and existence of these borrowings. Qualified opinionRepetitiveAs the Loan accounts have been classified as NPA, there were no communications from Lenders regarding outstanding balancesNA <br /> naNAThe balances pertaining to creditors, debtors, other current assets, other financial liabilities and banks are subjected to external confirmation. While we noted that the Company has initiated the process of obtaining confirmations, the Company has not received responses from various parties and for the differences in the balances confirmations received, the company is in the process of reconciliations and confirmations. Consequently, we are unable to comment on the accuracy, completeness and validity of the reported balances and the appropriateness of the accounting treatment adopted by the company in accordance with the applicable accounting standards.Qualified opinionRepetitiveThe balance confirmation from the parties have been sought for. We will provide you all the balance confirmations as and when received. Further, the balances are being reconciled, there are timing differences with respect to some parties, some parties have made an arbitrary claim. Further, no claim was ever made directly to the company prior to the commencement of CIRP, but made claim first time while submitting claim to RP during CIRP Proceeding. The company has not accepted any such additional claim other than recorded in books. In the absence of contractual obligation and no prior demand, as per IND AS 37, As per IND AS 37, the company is not liable to recognize the liability in books.nanaNAThe Company is in the process of obtaining confirmations from its vendors to identify whether they are covered under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act). Pending confirmations from all the vendors, the Company has not yet identified all applicable MSME vendors. Therefore, the disclosures required under the MSMED Act and the Companies Act, 2013, including any interest payable on delayed payments to MSME vendors, have not been made. Hence, we are unable to determine whether any interest is payable or assess its impact, if any, on the financial statements.Qualified opinionRepetitiveThe Company acknowledges the requirement under Section 22 of the MSMED Act, 2006 and Section 134 of the Companies Act, 2013 to disclose interest on delayed payments to suppliers registered as Micro, Small and Medium Enterprises. However, the Company has not received any confirmations or declarations from its vendors identifying themselves as MSMEs. In the absence of such information, the Company is unable to ascertain the financial impact of interest payable, if any. The disclosure made in the financials clearly state the above facts. The Company remains committed to complying with statutory requirements and will disclose such information once relevant data is made available.naNANAAs disclosed in Note 13 to the financial statements, the Company has recognized an amount of Rs.372.69 million under "Other Advances" representing advances paid towards acquisition of land in earlier years. Management has furnished the APIIC allotment letters, approvals for an extension of time till 31st December, 2025 to ensure the compliances in line with the allotment conditions and other related correspondences to substantiate the advances. However, as per the information and explanation furnished to us, the management is in the process of discussions and negotiations with the concerned authorities for obtaining further extension of time to comply the conditions laid down in the initial allotment letter. In the absence of sufficient and appropriate audit evidence regarding the outcome of such discussions and the recoverability of the advance, we are unable to determine whether any adjustment, including impairment or provision, to the carrying amount of the advance or the related disclosures in the financial statements is necessary.Qualified opinionWhether appeared first timeVivimed Labs Ltd (VLL), in the year 2008 wanted to obtain SEZ status for Ease of Exports. Further to obtain such status as per the norms laid down by the Government, the Company had to acquire 100 Hectares of Contiguous Land. So, VLL with the desire to obtain SEZ status for Ease of Exports and to establish State of Art Manufacturing Facility, started to acquire land directly from Owners & assignee land holders and Andhra Pradesh Industrial Infrastructure Corporation (APIIC)from 2008. In this regard, a detailed note is already submitted to Auditors. Documents evidencing above purchases have been shown to Auditors. The company had been spending amounts at regular intervals for various activities like Registration & Incidental Charges, Allotment Fee, Agriculture to Industrial Conversion Fee, Extension of Time Fee, Environmental Clarence Fee, Land Development Charges etc. All the said amounts aggregating to Rs. 37.26 Cr including Land Purchase consideration paid to APIIC and various landowners; that had been spent over the years had been presented as Advance for Land – Vizag.nanaNAThe Company has accrued commission expenses amounting to Rs.54.44 million as at March 31, 2026. Although the Company has furnished certain supporting documents and explanations, we could not obtain sufficient and appropriate audit evidence to substantiate that the commission expenses accrued and incurred. Consequently, we are unable to comment on the existence, completeness and accuracy of the provision recognised as at the reporting date.Qualified opinionRepetitiveThe Company has recognized a provision of Rs.54.44 million towards commission expenses in accordance with Ind AS 37, considering the existence of a constructive obligation arising from sales transactions and established business practice. The Company is in the process of obtaining supporting documents, confirmations, and other relevant evidence from agents / distributors to substantiate the measurement of the obligation. Management believes that the provision recognized is prudent and reflects the best estimate of the obligation at this stage. The Company is committed to completing the documentation process and will provide the necessary confirmations and supporting evidence in due coursenanaNASantosh VaralwarNoJarugula Siva PrasadG RamakrishnaHyderabad2026-07-1738814000003881400000003881400000